Press Room

ASD-HIPROS Learning Lab

Start
Thursday, July 29, 2021 - 00:00
End
Thursday, August 12, 2021 - 00:00
Location: online
Schedule meeting with Hovione ASD-HIPROS Learning Lab | Hovione

Join our exclusive Learning Lab at CPhI North America

ASD-HIPROS - A new platform for quick and effective 
formulation screening for Amorphous Solid Dispersions by Spray Drying”

 

Join our expert. In just 20 minutes you will learn:

  1. Introduction to Hovione’s new formulation screening platform by Spray Drying
  2. Learn about the advantages of a platform that integrates in silico computational models, formulation, analytical development
  3. Get to know more about Hovione’s extensive expertise in Spray Drying

 

REGISTER NOW

 

Synopsis

The number of drug candidates that present low solubility issues has been increasing over the past years. Amorphous Solid Dispersions (ASDs) are an established platform to address bioavailability challenges of poorly soluble drug candidates, offering many of the advantages of more conventional solid oral dosage forms while providing faster dissolution rates and higher drug concentrations. Suboptimal formulations of poorly soluble compounds may result in clinical failures, ultimately increasing the development timeline and associated costs towards identifying a winning candidate. Register now!

 

Targeted at APIs with poor solubility issues, ASD-HIPROS, Hovione’s Intelligent Proprietary Screening, is a methodology able to evaluate if formulations by Spray Drying are viable candidates towards solving poor bioavailability issues. Equipped with a computational platform coupled with state-of-the-art analytical and spray drying technologies, this platform is able to deliver optimal formulations in record time with minimal consumption of API, maximizing the chance of identifying a successful formulation and accelerating development towards clinical supplies.

 

Who should attend:

  1. Formulators
  2. Scientists
  3. Investigators and Research fellows
  4. R&D personnel
  5. Technical services personnel

 

REGISTER NOW

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024